Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients (HOPE)

AbbVie

Status: Completed

Conditions: Hidradenitis Suppurativa

Treatments: Biological: Adalimumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02739828

P15-692

Details and patient eligibility

About

The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.

Enrollment: 24 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Hidradenitis Suppurativa
• Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC)
• Willingness to sign and date a Patient Information/Informed Consent Form

Exclusion criteria

• Prior biologic treatment discontinued <6 months before the baseline visit
• Patient not able to understand the language of the provided patient questionnaires
• History of non-compliance with medication or a medical history that could enhance non-compliance with medication, as determined by the investigator

Trial design

24 participants in 1 patient group

Patients with Hidradenitis Suppurativa

Description:

Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.

Treatment:

Biological: Adalimumab